CCL5 and colorectal carcinoma: Consistently, Halama et al. found that blocking the CCR5/CCL5 axis with the CCR5 antagonist Maraviroc (MVC) in functional organoids derived from metastatic colorectal cancer (CRC) patients, determined a macrophage repolarization with anti-tumoral effects.